Immunomodulation, part I: pentoxifylline.
PTXF appears to be a promising adjunct to antibiotic therapy in neonatal sepsis. No adverse effects were noted in either study reported in the literature. However, there is a need for large randomized clinical trials to confirm or refute the role of PTXF in the treatment of sepsis in neonates. Clinically important comorbidities such as chronic lung disease, periventicular leukomalacia, duration of assisted ventilation, and NEC should be evaluated as a part of these studies. Comparison of PTXF with immunomodulatory agents such as colony-stimulating factors and intravenous immunoglobulins is suggested. Part II of this five-part series on immunomodulation will explore the use of colony-stimulating factors in neonates. Other topics will include the amino acid glutamine, intravenous immunoglobulins, and probiotics.
Bell
Susan Givens
SG
NICU, All Children's Hospital, St Petersburg, Florida, USA.
D002986:Clinical Trials as Topic; D016207:Cytokines / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D007231:Infant, Newborn; D007249:Inflammation; D015931:Intensive Care, Neonatal / Q000379:methods; D010431:Pentoxifylline / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D010726:Phosphodiesterase Inhibitors / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D018805:Sepsis / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome
D016207:Cytokines; D007155:Immunologic Factors; D010726:Phosphodiesterase Inhibitors; D010431:Pentoxifylline